• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    10/30/23 1:30:51 PM ET
    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • Miromatrix Medical (NASDAQ:MIRO) shares increased by 217.2% to $3.3 during Monday's regular session. The current volume of 2.9 million shares is 15262.3% of Miromatrix Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $90.0 million.
    • Eargo (NASDAQ:EAR) stock moved upwards by 52.38% to $2.56. Trading volume for Eargo's stock is 3.0 million as of 13:30 EST. This is 8069.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $53.1 million.
    • Reviva Pharmaceuticals (NASDAQ:RVPH) stock increased by 43.25% to $5.37. Trading volume for this security as of 13:30 EST is 28.1 million, which is 15724.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $121.6 million.
    • Motus GI Hldgs (NASDAQ:MOTS) shares increased by 35.65% to $0.56. The current volume of 9.0 million shares is 5804.7% of Motus GI Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $3.2 million.
    • BioXcel Therapeutics (NASDAQ:BTAI) shares moved upwards by 25.88% to $3.81. BioXcel Therapeutics's stock is trading at a volume of 11.1 million shares as of 13:30 EST. This is 435.7% of its average full-day volume over the last 100 days. The company's market cap stands at $111.6 million.
    • VYNE Therapeutics (NASDAQ:VYNE) shares rose 25.24% to $2.81. As of 13:30 EST, this security is trading at a volume of 18.6 million shares, making up 117219.3% of its average full-day volume over the last 100 days. The company's market cap stands at $9.2 million.

    Losers

    • LumiraDx (NASDAQ:LMDX) shares declined by 27.2% to $0.09 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 14.9 million shares, making up 250.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.8 million.
    • Qualigen Therapeutics (NASDAQ:QLGN) shares decreased by 22.86% to $0.66. The company's market cap stands at $3.3 million.
    • Tenax Therapeutics (NASDAQ:TENX) shares declined by 20.95% to $0.2. Trading volume for Tenax Therapeutics's stock is 1.1 million as of 13:30 EST. This is 239.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.7 million.
    • Better Therapeutics (NASDAQ:BTTX) stock declined by 16.59% to $0.15. Trading volume for this security as of 13:30 EST is 1.7 million, which is 114.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.2 million.
    • ABVC BioPharma (NASDAQ:ABVC) shares decreased by 15.94% to $1.16. The current volume of 2.7 million shares is 152.6% of ABVC BioPharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $4.5 million.
    • Biotricity (NASDAQ:BTCY) stock declined by 15.83% to $1.17. Trading volume for this security as of 13:30 EST is 55.1K, which is 211.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $BTAI
    $BTCY
    $BTTX

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    VYNE Therapeutics Inc.
    $VYNE
    11/18/2024$8.00Buy
    BTIG Research
    Tenax Therapeutics Inc.
    $TENX
    10/24/2024$16.00Outperform
    Leerink Partners
    Tenax Therapeutics Inc.
    $TENX
    10/14/2024$16.00Buy
    Guggenheim
    Tenax Therapeutics Inc.
    $TENX
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Reviva Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00

    9/29/25 9:59:06 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Tenax Therapeutics with a new price target

    Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00

    9/8/25 8:59:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

    NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,500,785 shares (the "Shares") of common stock, par value $0.001 per share ("Common Stock") (or common stock equivalents in lieu thereof), and accompanying warrants (the "Accompanying Warrants") to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant. The Accompanying

    3/11/26 4:20:00 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the "Shares") of common stock, par value $0.001 per share ("Common Stock") (or common stock equivalents in lieu thereof), and accompanying warrants (the "Accompanying Warrants") to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per comm

    3/10/26 2:36:00 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress. "We are pleased to announce that we have recently achieved our randomization target

    3/10/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    SEC Filings

    View All

    SEC Form 8-K filed by VYNE Therapeutics Inc.

    8-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    3/11/26 4:57:52 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by BioXcel Therapeutics Inc.

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    3/11/26 4:30:35 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by BioXcel Therapeutics Inc.

    424B5 - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    3/11/26 8:09:22 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    SEC Form 4 filed by Interim CFO Mcgauley Thomas

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    2/3/26 5:57:56 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Davidson Michael H.

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    1/13/26 9:49:18 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Giordano Christopher Thomas

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    1/13/26 9:37:38 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Financials

    Live finance-specific insights

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

    Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to

    12/17/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $ABVC
    $BTAI
    $BTCY
    $BTTX
    Leadership Updates

    Live Leadership Updates

    View All

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

    CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). "We are

    1/22/25 8:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Appoints John H. Johnson as Executive Chairman

    Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

    12/20/24 7:00:00 AM ET
    $APLT
    $RVPH
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care